US Medtech Urges Caution To Growing Push For 'Real-World' Device Evaluation System
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is stepping up efforts to develop and launch a new 'national evaluation system' for medical devices that relies on shared-access registries, claims data, health records and other electronic data, but industry advocates are cautioning against moving too fast. Companies worry about unintended consequences and say more details are needed on how the broad-based initiative to expand availability of "real-world" evidence for devices will impact the medtech innovation cycle.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.